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Abstract
Purpose The tumour microenvironment in older patients is subject to changes. The tumour–stroma ratio (TSR) was evaluated 
in order to estimate the amount of intra-tumoural stroma and to evaluate the prognostic value of the TSR in older patients 
with breast cancer (≥ 70 years).
Methods Two retrospective cohorts, the FOCUS study (N = 619) and the Nottingham Breast Cancer series (N = 1793), were 
used for assessment of the TSR on haematoxylin and eosin stained tissue slides.
Results The intra-tumoural stroma increases with age in the FOCUS study and the Nottingham Breast Cancer series (B 
0.031, 95% CI 0.006–0.057, p = 0.016 and B 0.034, 95% CI 0.015–0.054, p < 0.001, respectively). Fifty-one per cent of the 
patients from the Nottingham Breast Cancer series < 40 years had a stroma-high tumour compared to 73% of the patients 
of ≥ 90 years from the FOCUS study. The TSR did not validate as an independent prognostic parameter in patients ≥ 70 years.
Conclusions The intra-tumoural stroma increases with age. This might be the result of an activated tumour microenviron-
ment. The TSR did not validate as an independent prognostic parameter in patients ≥ 70 years in contrast to young women 
with breast cancer as published previously.
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Introduction
Breast cancer is the leading malignancy in European women 
[1]. A major risk factor for breast cancer development is 
ageing [2].
In the last decade, the tumour microenvironment has 
gained interest in unravelling cancer development and cancer 
progression, but also as a source for new therapeutic targets 
and prognostic parameters. The tumour microenvironment, 
i.e. tumour stroma, consists of a variety of structures and 
cells located in the extracellular matrix, such as immune 
cells, fibroblasts and endothelial cells. Various processes in 
the tumour microenvironment are involved in tumour pro-
gression by influencing the proliferation of cancer cells, the 
epithelial–mesenchymal transition, tumour metabolism and 
dissemination capabilities [3]. Epidemiological and clinico-
pathological characteristics are different in older patients 
with breast cancer compared to their younger counter-
parts [4–7]. The biology of breast cancer is age dependent 
in which alterations in extracellular matrix and products 
secreted by senescent fibroblasts are thought to promote 
late-onset breast tumourigenesis; however, the extent is still 
unknown [8]. Research into the molecular profile of older 
patients with triple negative breast cancer showed a differ-
ent stromal microenvironment favourable for tumourigen-
esis, in which senescence-associated secretory profile and 
autophagy are important aberrant stromal features induced 
with increasing age [9].
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A widely researched prognostic marker based on the 
tumour-microenvironment is the tumour–stroma ratio (TSR). 
The TSR reflects the ratio between tumour cells and stro-
mal cells and is visually assessed with conventional light 
microscopy. Previous studies have shown that the TSR is a 
valuable prognosticator for breast cancer patients, whereby 
tumours with a high-stromal content are associated with a 
poor clinical outcome [10–18]. This effect was observed and 
validated in the overall group of breast cancer patients and 
clinically relevant subgroups [18].
In the current literature, older patients are often defined 
as patients of 70 years and older [19]. In older patients 
with breast cancer, better risk stratification is desirable. 
Whilst breast cancer mortality in the total group of patients 
with breast cancer has decreased over the last decade, this 
decrease is lower or absent in older patients. This leads to an 
increased survival gap between older and younger patients 
with breast cancer [20–23]. Invasive breast tumours in the 
ageing women are thought to have a more favourable biology 
compared to younger females. Improvement of prognostic 
tools is needed for more accurate prediction of prognosis in 
the older breast cancer patient, considering that only very 
few older patients with breast cancer aged over 70 years 
receive chemotherapy [24]. More accurate stratification of 
disease aggressiveness could contribute in shared-decision 
making on the extent of adjuvant therapy. This may mini-
mise the risk of undertreatment which may contribute in the 
survival gap between younger and older patients with breast 
cancer. Although extensive research in population-based 
studies showed that the TSR is an important prognosticator 
in women with breast cancer, none of these studies have 
focused on its significance in the older female population.
Therefore, the aims of this study were (1) to investigate 
the amount of intra-tumoural stroma by the assessment of 
the TSR in older patients with breast cancer and (2) to evalu-
ate the prognostic value of the TSR in women diagnosed 
with breast cancer at the age of 70 years or older.
Materials and methods
Study population
This study included two databases with retrospectively 
collected clinical data from women diagnosed with breast 
cancer.
The FOCUS study
The FOCUS study consisted of a population based cohort of 
women aged 65 years and older, who were diagnosed with 
breast cancer (N = 3672) between 1997 and 2004 in Com-
prehensive Cancer Centre Region West (the Netherlands). 
Women with a history of cancer or in situ tumours, neo-
adjuvant therapy, distant metastasis at time of diagnosis, 
age under 70 years or with no available tumour tissue were 
excluded. In total, 1577 women were suitable for analyses. 
This cohort was used to answer both study aims, the evalua-
tion of the amount of intra-tumoural stroma and the prognos-
tic value of the TSR in the older women with breast cancer.
The Nottingham Breast Cancer series
The Nottingham Breast Cancer series (N = 1809) is a cohort 
of women ≤ 70 years of age presenting with primary inva-
sive breast cancer without distant metastasis, and primary 
treated with surgery in Nottingham City Hospital between 
1993 and 2002. Patients were included if haematoxylin and 
eosin (H&E) stained tissue slides and clinical information 
(patients and tumour characteristics and survival data) were 
available. This study was used for the evaluation of the 
amount of intra-tumoural stroma with the increase of age.
For standard clinical care all resected tumours were 
assessed by a pathologist, according to the currently applied 
pathological standards. The clinical data from the Notting-
ham Breast Cancer series were anonymized and the study 
was approved by the Nottingham Research Ethics Commit-
tee 2 under the title ‘Development of a molecular genetic 
classification of breast cancer’. All samples from the FOCUS 
study were also anonymised and data were handled accord-
ing to national ethical guidelines (“Code for Proper Second-
ary Use of Human Tissue”, Dutch Federation of Medical 
Scientific Societies).
Tumour–stroma ratio assessment
The tissues slides from the FOCUS study were assessed 
for the TSR by visual eyeballing with a conventional light 
microscope on standard H&E stained tissue slides, as 
described previously by our group [10, 25]. The most stroma 
rich area on the slide was selected with a 5× objective. A 
10× objective was used to select the final most stroma abun-
dant area. The H&E slides from the Nottingham Breast Can-
cer series were digital assessed via CaseViewer 2.2 for win-
dows (3D HISTECH Ltd.). The original H&E slides were 
scanned with a 20× magnification using 3D Histech Pano-
ramic 250 Flash II (3DHISTECH Ltd., Budapest, Hungary). 
Also for digital assessment the most stroma abundant area 
was selected. In the most stroma rich field a circle with an 
area of 3.1 mm2 was annotated. This area corresponded with 
the magnification used in our previous published research 
[26]. The next steps in the assessment of the TSR on digital 
images and conventional images were performed in the same 
manner. The percentage of stromal cells compared to tumour 
cells in the selected area were scored by increments of 10%. 
The selected area required tumour cells at all borders of 
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the image field. Stromal areas with post-biopsy effects were 
avoided. Finally, the determined percentages were divided 
into two categories; stroma-low (≤ 50% stroma) and stroma-
high (> 50% stroma) (Fig. 1). The tissues slides were double 
scored in a blinded fashion. If no consensus could be reached 
between the two observers a third observer was consulted. 
Consensus could be reached in all cases.
Statistical analyses
For statistical analyses IBM statistics v23.0 (SPSS, Inc., an 
IBM Company Chicago, IL, USA) was used. Relative sur-
vival analyses were performed with STATA SE software ver-
sion 12 (StataCorp, College Station, TX, USA). A Cohen’s 
Kappa was calculated for the evaluation of inter-observer 
agreement. A value above 0.6 was considered as good level 
of agreement. To evaluate the difference of patient charac-
teristics between women with stroma-low or stroma-high 
tumours a χ2 test was used in case of categorical variables. 
The distribution of numerical variables was tested with the 
Shapiro–Wilk test. Non-parametric continuous variables 
were evaluated using Mann–Whitney U test. Linear regres-
sion analysis was performed to investigate the association 
between age (continue) and the intra-tumoural stroma in per-
centage (increments of 10%). The linear regression analyses 
was adjusted for tumour size, histology, oestrogen receptor 
(ER) status, progesterone receptor (PR) status, human epi-
dermal growth factor 2 (HER2) status, triple negative (TN) 
status and grade, as these parameters might influence the 
amount of intra-tumoural stroma.
The primary endpoint was recurrence free period 
(RFP). The definition for RFP was time from diagnosis 
to local, regional or distant recurrence or contralateral 
breast cancer. Censoring was applied at the last date at 
which patients were known to be recurrence free and alive. 
The secondary endpoint was relative survival (RS). The 
observed overall survival (OS) among included patients 
divided by the expected survival in the sex-, age-, and 
calendar year matched general population was defined as 
relative survival. This was applied according to the Ederer 
II method with use of the ‘strs’ command in STATA. A 
relative survival rate of less than 100% at 10 years after 
diagnosis means that the survival of patients in the study 
is lower than expected when compared to survival of the 
general population. The relative survival data were cal-
culated at 10 years of follow-up. The relative excess risk 
of death (RER) was estimated using a multivariable gen-
eralized linear model with a Poisson distribution, based 
on collapsed relative survival data, using exact survival 
times. To assess the differences in RFP for our parameter 
of interest, the Kaplan–Meier curves were compared using 
log-rank test. This test was also used for analysing differ-
ent TSR cut-off values, other than the normally used 50% 
(i.e. ≤ 50% stroma is categorized as stroma-low and > 50% 
stroma is categorized as stroma-high). A p value lower 
than 0.05 was considered statistically significant for all 
analyses. Cox regression analyses were used to calculate 
the prognostic value of the TSR (univariate analysis and 
multivariate). The TSR was corrected for clinical impor-
tant confounders. The interaction term was introduced to 
evaluate the prognostic value of the TSR stratified by con-
founders. Power analyses showed that at least 618 patients 
of the FOCUS study must be analysed to reach a power of 
0.80 (1-β) with a type I error rate of 5% (α).
Fig. 1  Representative example of tumour–stroma ratio assessment a stroma-high tumour, b stroma-low tumour
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Results
Patients
The FOCUS study
In total, 1577 women included in the FOCUS study were 
eligible for inclusion. Based on power calculation, 627 
patients were selected via computer randomisation (mini-
mum of 618 patients). The included (N = 627) and excluded 
(N = 950) patients were compared for age, tumour grade, 
histological type, T-stage, N-stage, hormone receptor sta-
tus, HER2 status, type of operation, radiotherapy, chemo-
therapy and hormonal therapy. Between these two groups, 
only hormonal therapy showed to be statistically significant 
different (p = 0.003). In the included group, more patients 
were treated with hormonal therapy. However, hormonal 
therapy has no association with outcome (HR 1.01, 95% 
CI 0.66–1.54, p = 0.975). The median age of the excluded 
patients was 78 and the median age of the included women 
was 79 at time of diagnosis. Eight slides were not suitable 
for TSR assessment due to poor quality of the staining.
The characteristics of the selected patients are described 
in Table 1. Cohen’s kappa inter-observer agreement was 0.77 
(33% of slides were scored in a double-blinded fashion).
The Nottingham Breast Cancer series
An external cohort of primary breast cancer patients diag-
nosed in Nottingham City Hospital was used for the evalu-
ation of the TSR in order to investigate alterations in the 
amount of intra-tumoural stroma. Due to bad quality of the 
tissue, 15 patients were excluded (0.8%), and one patient 
was excluded because clinical information regarding patients 
age was unknown. Finally, 1793 patients were used in the 
analyses. The mean age was 55. An overview of patient char-
acteristics, tumour characteristics and treatment is shown 
in Table 2. All slides were assessed by two observers. If no 
consensus could be reached a third observer was consulted. 
Consensus was reached in all cases.
Alterations in stromal amount with the increase 
of age
For the patients in the FOCUS study (N = 619), the 
Mann–Whitney U test showed a significant associa-
tion between age and TSR (p = 0.020). By evaluating 
the TSR, the results showed a higher amount of intra-
tumoural stroma with the increase of age (B 0.025, 95% 
CI 0.004–0.045, p = 0.018). In the group of patients 
between 70 and < 75 years of age, 63% of the tumours 
were assessed as stroma-high compared to 73% of the 
tumours in patients aged 90 years or older (Fig. 2a).
Table 1  Statistically significant difference between stroma-low and 
stroma-high tumours in the FOCUS study
NST no special type, ER estrogen receptor, PR progesterone receptor, 
HER2 human epidermal growth factor receptor 2, MST mastectomy, 
BCS breast conserving surgery. Missing values were excluded from 
this analyses
N Stroma-low 
(%) (N = 204)
Stroma-high 
(%) (N = 415)
p value
Age (in years)
619 79 (mean) 80 (mean) 0.020
Grade
 I 82 31 (22.0) 51 (17.3) 0.126
 II 198 69 (48.9) 129 (43.9)
 III 155 41 (29.1) 114 (38.8)
Histological type
 Invasive 
carcinoma of 
NST
471 148 (72.5) 323 (77.8) 0.171
 Lobular 65 28 (13.7) 37 (8.9)
 Other 83 28 (13.7) 55 (13.3)
Tumour size
 pT1 254 96 (47.1) 158 (38.1) 0.014
 pT2 286 92 (45.1) 194 (46.7)
 pT3/4 79 16 (7.8) 63 (15.2)
Tumour involvement in the lymph nodes
 Negative 353 134 (66.3) 219 (54.2) 0.004
 Positive 253 68 (33.7) 185 (45.8)
ER status
 Negative 95 33 (18.9) 62 (16.9) 0.574
 Positive 447 142 (81.1) 305 (83.1)
PR status
 Negative 195 64 (38.8) 131 (37.8) 0.822
 Positive 317 101 (61.2) 216 (62.2)
HER2 status
 Negative 484 151 (76.3) 333 (82.0) 0.096
 Positive 120 47 (23.7) 73 (18.0)
Type of surgery
 BCS 181 68 (33.3) 113 (27.2) 0.117
 MST 438 136 (66.7) 302 (72.8)
Radiotherapy
 No 366 121 (59.3) 245 (59.0) 0.947
 Yes 253 83 (40.7) 170 (41.0)
Chemotherapy
 No 602 199 (97.5) 403 (97.1) 0.753
 Yes 17 5 (2.5) 12 (2.9)
Hormonal therapy
 No 303 112 (54.9) 191 (46.0) 0.038
 Yes 316 92 (45.1) 224 (54.0)
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To evaluate this age-effect in an independent cohort, the 
Nottingham Breast Cancer series (N = 1793) consisting of 
breast cancer patients of ≤ 70 years of age was assessed. 
The Mann–Whitney U test showed a significant association 
between age and TSR (p = 0.003). In this patient cohort, 
the evaluation of the TSR showed that the amount of intra-
tumoural stroma also increases with age (B 0.033, 95% CI 
0.014–0.053, p = 0.001). Of the patients under the age of 
40, 51% were scored as stroma-high compared to 66% of 
patients between the 65 and 70 years of age (Fig. 2b).
Linear regression was adjusted for tumour size, histology, 
ER status, PR status, HER2 status, TN status and grade in the 
FOCUS study and the Nottingham Breast Cancer series (B 
0.031, 95% CI 0.006–0.057, p = 0.016 and B 0.034, 95% CI 
0.015–0.054, p < 0.001, respectively). These results showed 
that the association between the amount of intra-tumoural 
stroma and age remained statistically significant after adjust-
ment of pathological tumour based characteristics.
Evaluation of the prognostic value of the TSR older 
patients with breast cancer
The FOCUS study
Most of the 619 tumours were categorised as stroma-high 
(67%). Eighty-five patients developed a tumour recur-
rence. Among stroma-high tumours, a higher number of 
patients with positive lymph nodes (p = 0.004), an advanced 
T-stage (p = 0.014) and hormonal therapy (p = 0.038) was 
observed. Older age was associated with stroma-high 
tumours (p = 0.020) (Table 1). After a follow-up period of 
10 years no statistical significant differences were observed 
in recurrence rates between stroma-low and stroma-high 
tumours, 18% versus 21% respectively (HR 1.13, 95% CI 
0.72–1.78, p = 0.602) (Fig. 3). The results in the multivariate 
Cox regression analysis were in line with the results of the 
univariate analysis (HR 1.02, 95% CI 0.59–1.78, p = 0.937) 
(Table 3). After 10 years of follow-up the relative survival 
rates of patients with stroma-low compared to stroma-high 
tumours were 90.2% versus 91.6%, respectively (RER 1.53, 
95% CI 0.31–7.47, p = 0.601).
The interaction term was added in the Cox regression 
analyses. These analyses showed no statistical significant 
value for the TSR if stratified by grade (p = 0.571), morphol-
ogy (p = 0.449), ER status (p = 0.598), PR status (p = 0.737), 
HER2 status (p = 0.721) or tumour size (p = 0.571).
In the FOCUS study, survival analyses were performed 
for the TSR at other cut-off values than the established 50%. 
The cut-off values ranged from 20% to 70% but none of the 
values showed statistically significant differences on clinical 
outcome (data not shown).
Discussion
The results in this study showed a significant association 
between age and intra-tumoural stroma percentage expressed 
with the TSR; a higher amount of intra-tumoural stroma 
was observed with the increase of age. This may be related 
to differences in tumour development and tumour microen-
vironment in older patients with breast cancer compared to 
their younger counterparts. For instance due to age-related 
pathological alterations which occur in the mamma, such as 
an increase in fat tissue and collagenous stroma as replace-
ment for glandular tissue [5, 27]. The extent of the altera-
tions in the extracellular matrix and products secreted by 
senescent fibroblasts in the promotion of late-onset breast 
tumourigenesis is still unknown. A different view on the role 
Table 2  Statistically significant difference between stroma-low and 
stroma-high tumours in the Nottingham Breast Cancer series
NST no special type, ER estrogen receptor, PR progesterone recep-
tor, HER2 human epidermal growth factor receptor 2. Missing values 
were excluded from this analyses
N Stroma-low 
(%) (N = 681)
Stroma-high 
(%) (N = 1113)
p value
Age (in years)
1793 54 (mean) 55 (mean) 0.003
Grade
 I 279 105 (15.4) 174 (15.6) 0.779
 II 733 272 (40.0) 461 (41.5)
 III 780 303 (44.6) 477 (42.9)
Histological type
 Invasive 
carcinoma of 
NST
1128 450 (66.1) 678 (61.0) 0.114
 Lobular 155 53 (7.8) 102 (9.2)
 Tubular 275 90 (13.2) 185 (16.6)
 Others 235 88 (12.9) 147 (13.2)
Tumour size
 T1 1146 505 (74.3) 641 (57.7) < 0.001
 T2 624 169 (24.9) 455 (41.0)
 T3 21 6 (0.9) 15 (1.4)
Tumour involvement in lymph nodes
 Negative 1127 452 (66.6) 675 (60.8) 0.013
 Positive 663 227 (33.4) 436 (39.2)
ER status
 Negative 331 151 (22.2) 180 (16.2) 0.002
 Positive 1462 530 (77.8) 932 (83.8)
PR status
 Negative 708 282 (42.0) 426 (38.7) 0.168
 Positive 1066 390 (58.0) 676 (61.3)
HER2 status
 Negative 1572 594 (87.2) 978 (87.9) 0.650
 Positive 221 87 (12.8) 134 (12.1)
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of senescent cells is suggested in recent literature. Senes-
cent cells were previously thought to be tumour-protective, 
but recent research showed that these cells contribute to a 
tumour-promoting environment [8]. A dysregulated response 
between declining immune function (i.e. immunosenes-
cence) on one hand and a low grade chronic inflammation 
(i.e. inflammageing) on the other hand may lead to an altered 
tumour microenvironment that has impact on tumour devel-
opment and tumour growth in the ageing population, prob-
ably with the involvement of CD4+ and CD8+ T-cells [28]. 
Previous research showed decreased values of these immune 
cells in mammary tumours in older mice compared to their 
younger counterparts [29]. Brouwers et al. investigated the 
molecular profile of the microenvironment in older triple 
negative breast cancer patients. The authors provided evi-
dence that breast cancer in the older patients is associated 
with a different stromal microenvironment favourable for 
tumourigenesis, in which senescence-associated secretory 
profile and autophagy are important stromal features induced 
with age. As an illustration, the authors validated in an exter-
nal publicly available dataset a significant upregulation of 
fibroblast growth factor 13 (FGF13) in tissues of older breast 
cancer patients. This gene belongs to the fibroblast growth 
factor superfamily. Aberrant expression of this superfam-
ily is involved in tumour growth and invasion [9]. Another 
process that occurs with ageing are changes in the hormonal 
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Fig. 2  Percentage of patients with stroma-low and stroma-high tumours stratified by age category a the FOCUS study (N = 619), b the Notting-
ham Breast Cancer series (N = 1793)
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status. In postmenopausal women the production of oestra-
diol takes place in peripheral tissues instead of the produc-
tion in the ovaries in the premenopausal status. This change 
leads to a consistent but lower level of circulating oestrogen 
[30]. Postmenopausal women with relatively high systemic 
concentration of oestrogen have a higher risk of developing 
breast cancer [31]. The chance of random genetic errors is 
increased by the proliferative effect of oestrogens on breast 
epithelial cells [32, 33]. Whether these processes contribute 
to the increase of stroma-high patients is not known yet. 
Also the contradictory results in this study regarding the 
prognostic value of the TSR is not fully understood. These 
results are in strong contrast to the discriminating power 
of the TSR regarding to clinical outcome presented in the 
review of Kramer et al. The authors showed that patients 
with stroma-high tumours have a poor clinical outcome. 
This was observed in the overall patient with breast cancer 
and in clinically relevant subgroups such as triple negative 
tumours, oestrogen positive tumours and lymph node nega-
tive tumours [18]. Therefore, understanding and confirming 
of age-related changes in the microenvironment requires fur-
ther research.
Regarding the ageing patient, the tumours of older 
patients with breast cancer are for example more often 
receptor positive and have a lower grade [34]. In contrast to 
the more favourable biology, Van de Water et al. concluded 
that the clinical outcome in older patients with breast cancer 
must not be underestimated, as breast cancer relapse and 
disease specific mortality is higher in older breast cancer 
patients compared to their younger counterparts [35]. A 
study performed in Denmark showed results in line with Van 
de Water et al. The 5-year relative survival decreases with 
the increase of age; 90% for patients aged between 0 and 
69 years, 80% for patients aged 70–79, 73% for women aged 
80–89 years [22]. Also the frequently used online prediction 
tool PREDICT slightly overestimated the 10-years overall 
survival of patients aged ≥ 65 years and must especially be 
interpreted with caution in patients aged ≥ 75 years [36, 37]. 
Dutch guidelines contain no explicit recommendations about 
chemotherapy in the older patients, mainly due to the scarce 
amount of studies specifically focusing on older patients 
Table 3  Univariate and 
multivariate analyses for 
recurrence free period 
calculated by Cox regression 
analysis for the FOCUS study
NST no special type, HER2 human epidermal growth factor receptor 2, PR progesterone receptor, ER estro-
gen receptor, TSR tumour–stroma ratio
Univariate Multivariate
HR 95% CI p value HR 95% CI p value
Age 1.01 0.97–1.05 0.623 1.02 0.59–1.78 0.349
Grade
 I < 0.001 < 0.001
 II 1.28 0.52–3.17 1.29 0.47–3.53
 III 3.91 1.66–9.24 1.05 1.48–11.11
Tumour size
 ≤  2 cm 0.003 0.053
 > 2 cm 2.04 1.28–3.25 1.77 0.99–3.15
Histological type
 Invasive carci-
noma of NST
0.715 0.518
 Lobular 0.82 0.39–1.70 0.57 0.17–1.87
 Others 0.80 0.41–1.55 1.26 0.59–2.69
ER status
 Negative < 0.001 0.735
 Positive 0.39 0.25–0.63 1.13 0.56–2.26
PR status
 Negative 0.008 0.004
 Positive 0.54 0.35–0.85 0.41 0.22–0.75
HER2 status
 Negative 0.158 0.637
 Positive 1.43 0.87–2.34 0.86 0.47–1.60
TSR
 Stroma-low 0.602 0.937
 Stroma-high 1.13 0.72–1.78 1.02 0.59–1.78
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resulting in lack of evidence about the efficiency of chemo-
therapy in patients over 70 years. In daily clinical practice in 
the Netherlands, chemotherapy is advised in fit older patients 
over 70 years. Shared-decision making between oncologists 
and patients plays a role in this process. A better prediction 
rule for prognosis combined with research about the defini-
tion of ‘fit’, and the effectiveness and side effects of chemo-
therapy in older patients, might simplify decision making 
regarding adjuvant therapeutic options. Based on the result 
that TSR seems to be an important prognostic marker in 
patients under the age of 70 in contrast to older patients, we 
advocate for the importance of validating other prognostic 
parameters in older patients.
With respect to this study, the chosen endpoint might 
have an effect on the outcome of the prognostic value of the 
TSR. With RFP as primary endpoint, it remains possible that 
metastases or recurrences are not filed if the observation of 
disease relapse has no clinical consequence, for example 
if patients are unfit for further treatment. To minimise the 
effect of competing mortality on survival the second end-
point was determined as RS instead of OS. A final limitation 
of this study is that adjuvant treatment options have changed 
over the years. Advantages of the included studies are a long 
follow-up period and the amount of patients included in the 
FOCUS study. In order to give a more definitive conclusion 
about the prognostic value of the TSR in the older patient 
with breast cancer, a large observational population-based 
cohort study of older breast cancer patients treated follow-
ing current guidelines assembled in a detailed database 
with focus on recurrences and disease specific survival is 
necessary.
Conclusions
The intra-tumoural stroma increases with age. The TSR 
showed no correlation with survival in patients of 70 years 
or older in contrast to young women with breast cancer as 
published previously.
Acknowledgements We would like to thank Dr. G.J. Liefers and Dr. 
P.J.K. Kuppen for their valuable feedback and suggestions.
Funding This work was supported by Genootschap Lisse-Bollenstreek, 
Lisse, The Netherlands. No grant number applicable.
Data availability Data are available on request.
Compliance with ethical standards 
Conflict of interest The authors declare no potential conflicts of inter-
est.
Ethical standard All samples from the FOCUS study were anonymized 
and according to national ethical guidelines (“Code for Proper Sec-
ondary Use of Human Tissue”, Dutch Federation of Medical Scien-
tific Societies). The clinical data from the Nottingham Breast Cancer 
series were anonymized and the study was approved by the Notting-
ham Research Ethics Committee 2 under the title ‘Development of a 
molecular genetic classification of breast cancer’. The study was per-
formed in accordance with the 1964 Helsinki declaration and its later 
amendments. The research performed comply with the current laws 
of the country.
Informed consent No additional informed consent was required as all 
data were anonymized.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bet-
tio M, Gavin A, Visser O, Bray F (2018) Cancer incidence and 
mortality patterns in Europe: estimates for 40 countries and 25 
major cancers in 2018. Eur J Cancer 103:356–387
 2. DePinho RA (2000) The age of cancer. Nature 408:248–254
 3. van Pelt GW, Sandberg TP, Morreau H, Gelderblom H, van 
Krieken J, Tollenaar R, Mesker WE (2018) The tumour-stroma 
ratio in colon cancer: the biological role and its prognostic impact. 
Histopathology 73:197–206
 4. Pierga, J. Y., Girre, V., Laurence, V., Asselain, B., Dieras, V., 
Jouve, M., Beuzeboc, P., Fourquet, A., Nos, C., Sigal-Zafrani, 
B., Pouillart, P., and Institut Curie Breast Cancer Study, G (2004) 
Characteristics and outcome of 1755 operable breast cancers in 
women over 70 years of age. Breast 13:369–375
 5. Benz CC (2008) Impact of aging on the biology of breast cancer. 
Crit Rev Oncol Hematol 66:65–74
 6. Wildiers H, Kunkler I, Biganzoli L, Fracheboud J, Vlastos G, Ber-
nard-Marty C, Hurria A, Extermann M, Girre V, Brain E, Audisio 
RA, Bartelink H, Barton M, Giordano SH, Muss H, Aapro M 
(2007) Management of breast cancer in elderly individuals: rec-
ommendations of the International Society of Geriatric Oncology. 
Lancet Oncol 8:1101–1115
 7. Diab SG, Elledge RM, Clark GM (2000) Tumor characteristics 
and clinical outcome of elderly women with breast cancer. J Natl 
Cancer Inst 92:550–556
 8. Lodi M, Scheer L, Reix N, Heitz D, Carin AJ, Thiebaut N, Neu-
berger K, Tomasetto C, Mathelin C (2017) Breast cancer in elderly 
women and altered clinico-pathological characteristics: a system-
atic review. Breast Cancer Res Treat 166:657–668
 9. Brouwers B, Fumagalli D, Brohee S, Hatse S, Govaere O, Floris 
G, Van den Eynde K, Bareche Y, Schoffski P, Smeets A, Neven P, 
Lambrechts D, Sotiriou C, Wildiers H (2017) The footprint of the 
ageing stroma in older patients with breast cancer. Breast Cancer 
Res 19:78
 10. de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, 
Liefers GJ, Kuppen PJ, Tollenaar RA, Mesker WE (2011) Tumor-
stroma ratio in the primary tumor is a prognostic factor in early 
breast cancer patients, especially in triple-negative carcinoma 
patients. Breast Cancer Res Treat 125:687–696
Breast Cancer Research and Treatment 
1 3
 11. Dekker TJA, van de Velde CJH, van Pelt GW, Kroep JR, Julien JP, 
Smit VTHBM, Tollenaar RAEM, Mesker WE (2013) Prognostic 
significance of the tumor-stroma ratio: validation study in node-
negative premenopausal breast cancer patients from the EORTC 
perioperative chemotherapy (POP) trial (10854). Breast Cancer 
Res Treat 139:371–379
 12. Downey CL, Thygesen HH, Sharma N, Shaaban AM (2015) Prog-
nostic significance of tumour stroma ratio in inflammatory breast 
cancer. Springerplus 4:68
 13. Downey CL, Simpkins SA, White J, Holliday DL, Jones JL, Jor-
dan LB, Kulka J, Pollock S, Rajan SS, Thygesen HH, Hanby AM, 
Speirs V (2014) The prognostic significance of tumour-stroma 
ratio in oestrogen receptor-positive breast cancer. Br J Cancer 
110:1744–1747
 14. Gujam FJ, Edwards J, Mohammed ZM, Going JJ, McMillan DC 
(2014) The relationship between the tumour stroma percentage, 
clinicopathological characteristics and outcome in patients with 
operable ductal breast cancer. Br J Cancer 111:157–165
 15. Moorman AM, Vink R, Heijmans HJ, van der Palen J, Kouwen-
hoven EA (2012) The prognostic value of tumour-stroma ratio in 
triple-negative breast cancer. Ejso 38:307–313
 16. Roeke T, Sobral-Leite M, Dekker TJA, Wesseling J, Smit V, Tolle-
naar R, Schmidt MK, Mesker WE (2017) The prognostic value of 
the tumour-stroma ratio in primary operable invasive cancer of the 
breast: a validation study. Breast Cancer Res Treat 166:435–445
 17. Vangangelt KMH, van Pelt GW, Engels CC, Putter H, Liefers GJ, 
Smit V, Tollenaar R, Kuppen PJK, Mesker WE (2017) Prognostic 
value of tumor-stroma ratio combined with the immune status 
of tumors in invasive breast carcinoma. Breast Cancer Res Treat 
168:601–612
 18. Kramer CJH, Vangangelt KMH, van Pelt GW, Dekker TJA, Tol-
lenaar R, Mesker WE (2018) The prognostic value of tumour-
stroma ratio in primary breast cancer with special attention to 
triple-negative tumours: a review. Breast Cancer Res Treat 
173:55–64
 19. Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler 
I, Reed M, Ciatto S, Voogd AC, Brain E, Cutuli B, Terret C, 
Gosney M, Aapro M, Audisio R (2012) Management of elderly 
patients with breast cancer: updated recommendations of the 
International Society of Geriatric Oncology (SIOG) and European 
Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 
13:e148–e160
 20. Smith BD, Jiang J, McLaughlin SS, Hurria A, Smith GL, 
Giordano SH, Buchholz TA (2011) Improvement in breast cancer 
outcomes over time: are older women missing out? J Clin Oncol 
29:4647–4653
 21. Holleczek B, Brenner H (2012) Trends of population-based breast 
cancer survival in Germany and the US: decreasing discrepancies, 
but persistent survival gap of elderly patients in Germany. BMC 
Cancer 12:317
 22. Jensen JD, Cold S, Nielsen MH, Jylling AM, Soe KL, Larsen 
LB, Ewertz M, Academy of Geriatric Cancer Research (2016) 
Trends in breast cancer in the elderly in Denmark, 1980–2012. 
Acta Oncol 55(Suppl 1):59–64
 23. Bastiaannet E, Portielje JE, van de Velde CJ, de Craen AJ, van 
der Velde S, Kuppen PJ, van der Geest LG, Janssen-Heijnen ML, 
Dekkers OM, Westendorp RG, Liefers GJ (2011) Lack of survival 
gain for elderly women with breast cancer. Oncologist 16:415–423
 24. Derks, M. G. M., Bastiaannet, E., Kiderlen, M., Hilling, D. E., 
Boelens, P. G., Walsh, P. M., van Eycken, E., Siesling, S., Brog-
gio, J., Wyld, L., Trojanowski, M., Kolacinska, A., Chalubinska-
Fendler, J., Goncalves, A. F., Nowikiewicz, T., Zegarski, W., 
Audisio, R. A., Liefers, G. J., Portielje, J. E. A., van de Velde, 
C. J. H., and Group, E. B. C (2018) Variation in treatment and 
survival of older patients with non-metastatic breast cancer in 
five European countries: a population-based cohort study from 
the EURECCA Breast Cancer Group. Br J Cancer 119:121–129
 25. Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, 
Tanke HJ, Tollenaar RA (2007) The carcinoma-stromal ratio of 
colon carcinoma is an independent factor for survival compared 
to lymph node status and tumor stage. Cell Oncol 29:387–398
 26. van Pelt GW, Kjaer-Frifeldt S, van Krieken J, Al Dieri R, Morreau 
H, Tollenaar R, Sorensen FB, Mesker WE (2018) Scoring the 
tumor-stroma ratio in colon cancer: procedure and recommenda-
tions. Virchows Arch 473:405–412
 27. LaBarge MA, Mora-Blanco EL, Samson S, Miyano M (2016) 
Breast cancer beyond the age of mutation. Gerontology 
62:434–442
 28. Jackaman C, Tomay F, Duong L, Abdol Razak NB, Pixley FJ, 
Metharom P, Nelson DJ (2017) Aging and cancer: the role of 
macrophages and neutrophils. Ageing Res Rev 36:105–116
 29. Provinciali M, Argentati K, Tibaldi A (2000) Efficacy of can-
cer gene therapy in aging: adenocarcinoma cells engineered to 
release IL-2 are rejected but do not induce tumor specific immune 
memory in old mice. Gene Ther 7:624–632
 30. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope 
C, Speizer FE (1995) Reproducibility of plasma hormone levels in 
postmenopausal women over a 2–3-year period. Cancer Epidemiol 
Biomarkers Prev 4:649–654
 31. Key T, Appleby P, Barnes I, Reeves G, Endogenous H, Breast 
Cancer Collaborative Group (2002) Endogenous sex hormones 
and breast cancer in postmenopausal women: reanalysis of nine 
prospective studies. J Natl Cancer Inst 94:606–616
 32. Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, 
progestogens, normal breast cell proliferation, and breast cancer 
risk. Epidemiol Rev 15:17–35
 33. Cohen SM, Ellwein LB (1990) Cell proliferation in carcinogen-
esis. Science 249:1007–1011
 34. Gennari R, Curigliano G, Rotmensz N, Robertson C, Colleoni 
M, Zurrida S, Nole F, de Braud F, Orlando L, Leonardi MC, 
Galimberti V, Intra M, Veronesi P, Renne G, Cinieri S, Audisio 
RA, Luini A, Orecchia R, Viale G, Goldhirsch A (2004) Breast 
carcinoma in elderly women: features of disease presentation, 
choice of local and systemic treatments compared with younger 
postmenopausal patients. Cancer 101:1302–1310
 35. van de Water W, Markopoulos C, van de Velde CJ, Seynaeve C, 
Hasenburg A, Rea D, Putter H, Nortier JW, de Craen AJ, Hille 
ET, Bastiaannet E, Hadji P, Westendorp RG, Liefers GJ, Jones SE 
(2012) Association between age at diagnosis and disease-specific 
mortality among postmenopausal women with hormone receptor-
positive breast cancer. JAMA 307:590–597
 36. de Glas NA, Bastiaannet E, Engels CC, de Craen AJ, Putter H, van 
de Velde CJ, Hurria A, Liefers GJ, Portielje JE (2016) Validity of 
the online PREDICT tool in older patients with breast cancer: a 
population-based study. Br J Cancer 114:395–400
 37. van Maaren MC, van Steenbeek CD, Pharoah PDP, Witteveen 
A, Sonke GS, Strobbe LJA, Poortmans PMP, Siesling S (2017) 
Validation of the online prediction tool PREDICT v. 2.0 in the 
Dutch breast cancer population. Eur J Cancer 86:364–372
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
